Erythromycin, clarithromycin, and azithromycin: Are the differences real?

Clinical Therapeutics

Volumn 18, Issue 1, 1996, Pages 56-72

  Amsden, Guy W ^a  

^a SAINT VINCENT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; RIFABUTIN; TERFENADINE; THEOPHYLLINE; ZIDOVUDINE;

ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; HYPOACUSIS; MICROBIOLOGY; NONSPECIFIC URETHRITIS; PREGNANCY; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; UTERINE CERVICITIS;

EID: 0029797383     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80179-2     Document Type: Article

References (63)

1. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: New macrolide antibiotics. Clin Pharm. 1992; 11:137-152.
2. Ballow CH, Amsden GW. Azithromycin: The first azalide antibiotic. Ann Pharmacother. 1992;26:1253-1261.
3. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73-82.
4. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: Overview and comparison with erythromycin. Infect Control Hosp Epidemiol. 1992;13:357-368.
5. Prescribing information for erythromycin, clarithromycin, and azithromycin. Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics Data Production Company; 1996:405-410, 426-427, 1944-1946.
6. Ballow CH, Amsden GW, Forrest A, Anderson AC. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin (C) and azithromycin (A) in normal subjects. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract A22.
7. Gladue RP, Bright CM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother. 1989;33: 277-282.
8. Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother. 1988;22:923-933.
9. Ishiguro M, Koga H, Kohno S, et al. Penetration of macrolides into human polymorphonuclear leukocytes. J Antimicrob Chemother. 1989;24:719-729.
10. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1994:492-528.
11. Goetschi B, Lode H, Harnacher J, et al. Comparative pharmacokinetics and tissue concentrations of macrolides. Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract A24.
12. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother. 1990;34:1056-1060.
13. Ballow CH, Amsden GW, Forrest A, et al. Multiple-dose serum and urine pharmacokinetics of oral azithromycin in normal healthy volunteers. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14, 1992; Anaheim, Calif. Abstract 215.
14. Fass RJ. Erythromycin, clarithromycin and azithromycin: Use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother. 1993;37: 2080-2086.
15. Hardy DJ, Hensey DM, Beyer JM, et al. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother. 1988;32: 1710-1719.
16. Barry AL, Fuchs PC, Brown SD. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics. J Antimicrob Chemother. 1995;35: 552-555.
17. Brown SD, Burton P, Rich T, et al. Susceptibility surveillance of US respiratory pathogen isolates to newer macrolide and azalide antibiotics. Presented at the 94th General Meeting of the American Society for Microbiology; May 23-27, 1994; Las Vegas, Nev.
18. Amsden GW, Ballow CH, Forrest A. Pharmacokinetics (PKs) of azithromycin (AZM) in serum, urine, PMNs, inflammatory (IB) and non-inflammatory (NB) blisters. Program and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; January 19-22, 1994; Venice, Italy. Abstract 182.
19. Pukander J. Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children. Program and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; January 19-22, 1994; Venice, Italy. Abstract 199.
20. Olsen KM, San Pedro GS, Gann LP, et al. Estimation of azithromycin concentrations in pulmonary tissues and serum after multiple oral doses in normal volunteers. Presented at the American Thoracic Society International Conference; May 21-24, 1995: Seattle, Wash.
21. Bahal N, Nahata MC. The new macrolìde antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother. 1992;26:46-55.
22. Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. 1993; 31(Suppl E):137-146.
23. Sturgill MG, Rapp RP. Clarithromycin: Review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother. 1992; 26:1099-1108.
24. Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother. 1993;31 (Suppl E): 153-162.
25. Karma P, Pukander J, Penttila M, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother. 1991;27(Suppl A):83-90.
26. Bachand RT. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A):91-100.
27. Howie VM. Eradication of bacterial pathogens from middle ear infections. Clin Infect Dis. 1992;14(Suppl 2):209-210.
28. Pozzi E, Grossi E, Pecori A, et al. Azithromycin versus clarithromycin in the treatment of acute exacerbations of chronic bronchitis. Curr Ther Res. 1994;55: 759-764.
29. Dark D. Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections. Am J Med. 1991; 91(Suppl 3A):31S-35S.
30. Davies BI, Maesen FPV, Gubbelman SR. Azithromycin (CP-62,993) in acute exacerbations of chronic bronchitis: An open clinical, microbiological and pharmacokinetic study. J Antimicrob Chemother. 1989;23:743-751.
31. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;91 (Suppl 3A):40S-45S.
32. Miller MF, Martin JR, Johnson P, et al. Erythromycin uptake and accumulation by human polymorphonuclear leukocytes and efficacy of erythromycin in killing ingested Legionella pneumophila. J Infect Dis. 1984;149:714-718.
33. Felmingham D, Robbins MJ, Sanghrajka M, et al. The in vitro activity of some 14-, 15-, and 16-membered macrolides against Staphylococcus spp., Legiomella spp., Mycoplasma spp. and Ureaplasma urealyticum. Drugs Exp Clin Res. 1991; 17:91-99.
34. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne legionnaires' disease. J Antimicrob Chemother. 1993;31 (Suppl E):171-176.
35. Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the site of pulmonary infections. Eur Respir J. 1990;3:886-890.
36. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1994;38:790-798.
37. Cassell GH, Drnec J, Waites KB, et al. Efficacy of clarithromycin against Mycoplasma pneumoniae. J Antimicrob Chemother. 1991;27(Suppl A):47-59.
38. Levine WC, Berg AO, Johnson RE, et al. Development of sexually transmitted diseases treatment guidelines, 1993: New methods, recommendations, and research priorities. Sex Transm Dis. 1994;21(Suppl 2):S96-S101.
39. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet. 1985;10:63-79.
40. Gardner MJ, Coates PE, Hilligoss DM, Henry EB. Lack of effect of azithromycin on the pharmacokinetics of theophylline in man. Presented at the Mediterranean Congress of Chemotherapy; May 24-29, 1992; Athens, Greece. Abstract 410.
41. Amsden GW. Review of the drug interaction profile of azithromycin. Program and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; January 19-22, 1994; Venice, Italy. Abstract 218.
42. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effects of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest. 1994;7:148-154.
43. Siepman N, Blahunka KS, Harris SI, Palmer RN. ECG changes observed following multiple dose co-administration of clarithromycin and terfenadine. Pharm Res. 1993;10:53-54.
44. Harris S, Morse I, Hilligoss DM, et al. Azithromycin and terfenadine: Lack of drug interaction, a double-blind, placebo-controlled study. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans, La. Abstract 597.
45. Rapeport WG, Dewland PM, Muirhead DC, Forster PL. Lack of an interaction between azithromycin and carbamazepine. Br J Clin Pharmacol. 1992;33:551P.
46. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: A case report. Epilepsia. 1993;34:161-162.
47. Tatum WO, Gonzalez MA. Carbamazepine toxicity in an epileptic induced by clarithromycin. Hosp Pharm. 1994;29: 45-46.
48. Richens A, Chu SY, Sennello L, Sonders R. Effect of multiple doses of clarithromycin on the pharmacokinetics of carbamazepine. Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 21-24, 1990; Atlanta, Ga. Abstract 760.
49. Gustavson LE, Chu SY, Mackenthun A, et al. Drug interaction between clarithromycin and oral zidovudine in HIV patients. Clin Pharmacol Ther. 1993;53:163. Abstract.
50. Petty B, Polis M, Haniewich S, et al. Pharmacokinetic assessment of clarithromycin plus zidovudine in HIV patients. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy: October 11-14, 1992; Anaheim, Calif. Abstract 24.
51. Polis M, Haniewich S, Kovachs J, et al. Dose escalation to determine the safety, maximally tolerated dose (MTD), and pharmacokinetics of clarithromycin with zidovudine in HIV-infected persons. Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago, III. Abstract 238.
52. Vance EA, Watson-Bitan M, Gustavson L, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1995;39:1355-1360.
53. Chave JP, Munafo A, Chatton JY, et al. Once-a-week azithromycin in AIDS patients: Tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother. 1992;36:1013-1018.
54. Gillum JG, Bruzzese VL, Israel DS, et al. Effect of multiple oral doses of clarithromycin (CLARY) on the pharmacokinetics of 2′,3′ dideoxyinosine (ddl) in patients infected with HIV. Program and Abstracts of the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. Abstract 451.
55. Datri 001 Study Group. Clarithromycin (CL) plus rifabutin (RFB) for MAC prophylaxis: Evidence for a drug interaction. Program and Abstracts of the First National Conference on Human Retroviruses and Related Infections; December 12-16, 1993; Washington, DC. Abstract 291.
56. Datri 001 Study Group. Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB). Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract A2.
57. Periti P, Mazzei T, Mini E, Novelli A. Adverse effects of macrolide antibacterials. Drug Safety. 1993;9:346-364.
58. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis. 1991;144:564-569.
59. Wallace MR, Miller LK, Nguyen M-T, Shields AR. Ototoxicity with azithromycin. Lancet. 1994;343:241.
60. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother. 1993;31(Suppl E):57-63.
61. Shiba K, Shindo N, Sakai O. Pharmacokinetics of azithromycin in patients with renal failure. Program and Abstracts of the Second International Conference on the Macrolides, Azalides, and Streptogramins; January 19-22, 1994; Venice, Italy. Abstract 188.
62. Bush MR, Rosa C. Azithromycin and erythromycin in the treatment of cervical chlamydial infection during pregnancy. Obstet Gynecol. 1994;84:61-63.
63. Pricing information for erythromycin, clarithromycin, and azithromycin. Red Book®. Montvale, NJ: Medical Economics Data Production Company; 1995:151, 231-234, 472.